AtopX

**AtopX** is an FDA-cleared, non-steroidal topical ointment developed by Turn Therapeutics for the management of atopic dermatitis (AD), irritant dermatitis, and radiation dermatitis. It utilizes the company's proprietary **PermaFusion** technology, a patented drug delivery system that permanently fuses liquid active ingredients into oil without emulsifiers, enabling deep skin penetration to address AD at its root cause by inhibiting key immune signals such as **IL-36** and **IL-31**. Applied twice daily, AtopX has demonstrated efficacy in reducing disease severity, with clinical data showing a 57% reduction in 7 days, and is being evaluated in a large-scale Phase II/IV adaptive trial (TT-003-301) involving ~400 pediatric and adult subjects (12-75 years) with mild, moderate, or severe AD, using endpoints like Investigator’s Global Assessment (IGA) responder rates and EASI-50.[1][4][8][10]

Brand names

AtopX

Other names

AtopX Eczema Emulsion